|
|
non-toxic mutant E112K of Cholera Toxin mCT-E112K |
|
Vaxjo ID |
105 |
|
Vaccine Adjuvant Name |
non-toxic mutant E112K of Cholera Toxin mCT-E112K |
|
Alternative Names |
mCT |
|
Adjuvant VO ID |
VO_0001347
|
|
Description |
E112K mCT is a mutated CT created by substituting a single amino acid in the ADP-ribosyltransferase active centre, glutamate to lysine at position 112 (Yamamoto et al., 2001). |
|
Stage of Development |
Research |
|
Function |
The mCT E112K has been shown to exhibit two distinct mechanisms for its adjuvanticity. Firstly, mCT enhanced the B7-2 expression of APCs. Secondly, this nontoxic CT derivative directly affected CD4+ T cells and selectively inhibited Th1 cytokine responses. mCT E112K, which lacks ADP-ribosyltransferase activity, enhanced identical levels of B7-2 expression on B cells and macrophages when compared with native CT (Yamamoto et al., 2001). |
| Related Vaccine(s) |
|
| References |
Yamamoto et al., 2001: Yamamoto M, McGhee JR, Hagiwara Y, Otake S, Kiyono H. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scandinavian journal of immunology. 2001; 53(3); 211-217. [PubMed: 11251876].
|
|
